News
Dr. Carrillo also suggested that the IDEAS study could set a useful precedent for wider reimbursement of other Alzheimer’s biomarker tests.
“Many current biomarkers in development for Alzheimer’s are similar to amyloid imaging in that they are not specific for Alzheimer’s disease and are known to occur with other dementias. In the future, coverage may also be questioned as to how they improve health outcomes in a clinical setting. Results from the IDEAS study will help create precedent and lay the groundwork for the type of information that will be needed for future biomarker approval and coverage.”
On Twitter @alz_gal